Informace o publikaci

Adjuvant therapies by anthocyanins potentially mitigating drug resistance and metastatic disease risks in stratified breast cancers: the 3PM-conceptual innovation targeted to NF-kappaB/EMT plasticity

Autoři	SVENTEKOVA Anita KUBATKA Peter SLANINOVÁ Iva NYKODÝMOVÁ Daniela HORNAKOVA Lubica TRBOLOVA Alexandra GONCHARENKO Vadim ŠMEJKAL Karel GOLUBNITSCHAJA Olga
Rok publikování	2026
Druh	Recenzovaný odborný článek
Časopis / Zdroj	EPMA JOURNAL
Fakulta / Pracoviště MU	Farmaceutická fakulta
Citace
www	https://link.springer.com/article/10.1007/s13167-026-00463-6
Doi	https://doi.org/10.1007/s13167-026-00463-6
Klíčová slova	Predictive preventive personalized medicine (PPPM / 3PM); Anthocyanins; Anthocyanidins; Therapy-resistant breast cancer; Triple-negative breast cancer; Trastuzumab resistance; Taxane resistance; NF-kappa B; Epithelial-mesenchymal transition; Drug sensitization; Mitochondrial homeostasis and biosensorics; Patient stratification; Chronic inflammation; Sympathetic overdrive phenotype
Popis	Therapy resistance in breast cancer is increasingly understood as a dynamic state transition driven by inflammatory survival signaling, phenotypic plasticity, and treatment-induced adaptive rewiring rather than as a single endpoint event. Although anthocyanins and anthocyanidins are widely discussed as anticancer phytochemicals, their relevance to the therapy resistance depends on their capacity to modify defined therapy-resistant states under pharmacologically meaningful conditions. Contextually, this article critically evaluates the preclinical evidence and proposes the 3PM-guided conceptual innovation for anthocyanin- and anthocyanidin-linked drug sensitization in therapy-resistant breast cancers, using specifically the NF-kappa B/EMT crosstalk as a functional lens. To this end, NF-kappa B/EMT signaling as the proposed target, per strong scientific evidence, is involved in pathways considered central for the phenotype-specific epigenetic regulation of health risks, malignant transformation, development of metastatic disease and therapy resistance. Finally, patient phenotyping and stratification, targeted risk mitigation and treatments tailored to individualized patient profiles are considered essential pillars for improved individual outcomes in the 3PM-guided paradigm.